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Abstract
Mas receptor (MasR) is a G protein-coupled receptor proposed as a candidate for mediating
the angiotensin (Ang)-converting enzyme 2-Ang (1–7) protective axis of renin–angiotensin sys-
tem. Because the role of this receptor is not definitively clarified, determination of MasR tissue
distribution and expression levels constitutes a critical knowledge to fully understanding its
function. Commercially available antibodies have been widely employed for MasR protein
localization and quantification, but they have not been adequately validated. In this study, we
carried on an exhaustive evaluation of four commercial MasR antibodies, following previously
established criteria. Western Blotting (WB) and immunohistochemistry studies starting from
hearts and kidneys from wild type (WT) mice revealed that antibodies raised against different
MasR domains yielded different patterns of reactivity. Furthermore, staining patterns appeared
identical in samples from MasR knockout (MasR-KO) mice. We verified by polymerase chain
reaction analysis that the MasR-KO mice used were truly deficient in this receptor as MAS tran-
scripts were undetectable in either heart or kidney from this animal model. In addition, we eval-
uated the ability of the antibodies to detect the human c-myc-tagged MasR overexpressed in
human embryonic kidney cells. Three antibodies were capable of detecting the MasR either by
WB or by immunofluorescence, reproducing the patterns obtained with an anti c-myc antibody.
In conclusion, although three of the selected antibodies were able to detect MasR protein at
high expression levels observed in a transfected cell line, they failed to detect this receptor in
mice tissues at physiological expression levels. As a consequence, validated antibodies that
can recognize and detect the MasR at physiological levels are still lacking.
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Introduction
Human Mas receptor (MasR) was described 30 years ago as a G protein–coupled receptor
(GPCR) with transforming activity [1]. Currently, it is classified as a class A orphan GPCR [2].
More specifically, it was the founding member of the Mas-related GPCR subfamily (Mrgprs)
consisting of mostly orphan receptors structurally homologous to MasR expressed in specific
subpopulations of sensory neurons that detect painful stimuli [2]. In addition to the human
gene, the MAS gene was isolated and characterized in rats and in mice. Highest levels of MasR
transcripts were found in brain and testis, but lower levels were also detected in other organs
such as heart and kidney [2–8]. The analysis of the human MAS cDNA sequence reveals an
open reading frame that codes for a 325-amino-acid protein, whereas the mouse and rat
homologues contain 324 amino acids [2, 6]. The predicted molecular weight (MW) of MasR is
approximately 37 kDa (Uniprot: P04201, P30554 and P12526). The availability of MasR
knockout (MasR-KO) mice facilitated the acquisition of information regarding the involve-
ment of this receptor in behavioral, cardiovascular and renal processes [9, 10]. Noteworthy,
multiple phenotypes are reported in literature for MasR-KO mice, showing both damaging
and protective effects of the absence of MasR on organs and tissues [9].
MasR has been functionally and pharmacologically linked to angiotensin (Ang)-(1–7) [9,
11]. This heptapeptide is an endogenously produced renin–angiotensin system (RAS) hor-
mone [12], mainly generated through the cleaving action of Ang-converting enzyme 2 (ACE2)
on Ang II [13, 14]. The ACE2/Ang-(1–7) axis is involved in many physiologic and pathophysi-
ological processes in several systems and organs, especially by opposing the detrimental effects
of inappropriate overactivation of the classical RAS axis formed by ACE, Ang II, and Ang II
type 1 (AT1) receptor [15]. Although MasR has been proposed as a candidate receptor for
mediating the ACE2-Ang (1–7) protective axis of RAS, there are reports about the participa-
tion of the Ang II type 2 (AT2) receptor [16,17] and the AT1 receptor [18] in the actions of
Ang-(1–7) as well as descriptions of other natural ligands for MasR, such as neuropeptide FF
(NPFF) [19, 20], Ang III, Ang IV [21] and angioprotectin [22]. Thus, so far, it is not clear
whether the interaction between Ang-(1–7) and MasR is mutually exclusive [9, 23].
As MasR has been suggested to participate in several physiological processes, the study of
its function has generated increased interest due to potential therapeutic applications [9, 24].
Because its role has not been definitively clarified, sensitive and specific detection of the MasR
protein is essential for studies aimed at elucidating its regulation in both physiological and
pathophysiological conditions. Commercially available MasR antibodies have been widely
used in investigations tending to determine MasR distribution, quantify its abundance and
analyze its interaction with other molecules. Remarkably, the specificity of antibodies directed
to several GPCRs has been questioned in many reports. This includes antibodies directed
against various subtypes of α1- and β-adrenoceptors [25–27], muscarinic [27, 28], dopamine
[29], galanin [30] as well as glucagon-like peptide-1 [31, 32] receptors. In many cases, multiple
antibodies were used, and none of them were found to be selective. This indicated that, unfor-
tunately, lack of specificity is frequent for GPCR antibodies [33]. More specifically, recent pub-
lications reported lack of specificity of commercially available AT1 [34, 35] and AT2 [36]
receptor antibodies and the resulting difficulties in defining RAS receptors expression [37, 38].
During preliminary experiments using mice with targeted deletion of the MAS gene, we
found contradicting results regarding the specificity of antibodies directed to MasR. As an ade-
quate validation analysis was lacking, we carried out an exhaustive evaluation of a panel of
commercial MasR antibodies. We followed a set of previously established validation criteria
based in the principles of antibody action that establish a reasonable degree of assurance that
the antibody being tested is actually targeting its correct antigen [33,34,36–42]. We focused on
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their utility for Western Blotting (WB), immunofluorescence (IF), and immunohistochemistry
(IHC) studies. We employed mice genetically deficient in MasR that allowed a definitive evi-
dence of antibody specificity, and also evaluated the ability of these antibodies to detect differ-
ent expression levels of the receptor through the use of a heterologous cell line overexpressing
the human MasR.
Materials and methods
Antibodies
Four commercial antibodies raised against different domains of the MasR were selected for
their validation. Two antibodies (sc-135063 and sc-54682) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA); AAR-013 was from Alomone Labs (Jerusalem, Israel)
and NLS1-1531 was from Novus Biologicals (Littleton, CO, USA). During the last phase of this
study Santa Cruz Biotechnology discontinued a large number of its polyclonal products
including sc-135063 and sc-54682 antibodies. The information of immunogen used, reactivity
and applications as provided by the manufacturers is presented in Fig 1.
Animals
To obtain Mas receptor knockout (MasR-KO) animals on a pure genetic background, MasR+/-
mice (mixed genetic background, 129 x C57BL/6) [10] were bred to the FVB/N mouse line
(Charles River, Sulzfeld, Germany) for seven generations at the Max Delbru¨ck Center for
Molecular Medicine. The selection for the MasR-KO allele was done by polymerase chain
reaction (PCR) with primers MAS12: 5´-GCCGTT GCC CTC CTG GCG CCT GGG-3´ and
Fig 1. Characteristics of MasR antibodies used in the study. pAb polyclonal antibody, H human, M mouse, R rat, C canine, B bovine, WB
western blot, IHC immunohistochemistry, ICC immunocytochemistry, IF immunofluorescence, IP immunoprecipitation, IFC indirect flow
cytometry, ELISA enzyme-linked immunosorbent assay.
https://doi.org/10.1371/journal.pone.0183278.g001
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NeoPVU: 5´-GGC AGC GCG GCT ATC GTG G-3´. Primers MAS10: 5´-GTACAG CTT CGA
AGA ATG GGA GGC CC-3´ and MAS14: 5´-CCTAAC TGA GCC ACC CTC ACC-3´were
used for the detection of wild-type alleles. Thereafter, F7 heterozygous males were bred with
F7 heterozygous females to generate the line FVB/N MasR-KO. Mice were maintained at the
transgenic animal facilities of the Laboratory of Hypertension (Federal University of Minas
Gerais, Belo Horizonte, Brazil) and were treated according to the international guidelines for
animal care. Nine-week-old male FVB/N wild type (WT) and FVB/N MasR-KO mice were
used for the experiments. The experimental protocol was approved by the ethics committee in
animal experimentation of the Federal University of Minas Gerais (protocol no. 006/05). The
animals were maintained under controlled light and temperature conditions and had free
access to water and standard diet.
Molecular construct
We used a MasR expression construct that consisted of the cDNA sequence corresponding to
the human MasR (accession number: NM_002377.2) fused to the c-myc tag peptide at N-ter-
minal. The construct was synthesized and subcloned into the pcDNA 3.1 (+) mammalian
expression vector between BamHI and EcoRI restriction sites by Life Technologies (Grand
Island, NY) (pcDNA 3.1/c-myc-MasR). An empty vector [pcDNA 3.1 (+)] was used both as
control and to deliver an equal amount of plasmid per transfection in Western Blotting (WB)
and in immunofluorescence (IF) experiments.
Cell culture and transient transfections
Human embryonic kidney (HEK293T) cells were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). They were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine and
5 μg/ml gentamicin and maintained at 37˚C in a humidified atmosphere containing 5% CO2.
For transient transfections, the cDNA constructs were transfected using Lipofectamine 2000
(Life Technologies). The transfection protocol was optimized as recommended by the suppli-
ers. For IF experiments, approximately 2 x 104 cells were seeded on 0.01% (w/v) poly-L-lysine
pre-treated 15 mm coverslips and grown for 24 h. Transient cotransfections were performed
with 0.25 μg pcDNA 3.1/c-myc-MasR and 0.25 μg empty plasmid pcDNA 3.1. Cells transfected
with 0.5 μg of empty plasmid pcDNA 3.1 were used as controls. For WB experiments, approxi-
mately 5 x 105 cells were seeded in 12-well culture plates and the following day were trans-
fected with 0, 0.2, or 0.5 μg of pcDNA 3.1/c-myc-MasR. Empty plasmid pcDNA 3.1 was
utilized to deliver an equal amount of plasmid per transfection.
Protein extraction from rodent tissues and cultured cells
WT and MasR-KO mice were anesthetized by the intraperitoneal administration of a mixture
of ketamine and xylazine (60 and 10 mg/kg, respectively), and submitted to the surgical proce-
dure as soon as anesthesia was assured by the loss of pedal and corneal reflexes. The abdominal
cavity was opened and the heart and kidney were removed. Tissue were homogenized at the
ratio 0.1 g/1 ml in a buffer containing 1% Triton, 100 mM Hepes, 100 mM sodium pyrophos-
phate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium vanadate, 2 mM phenyl-
methylsulfonyl fluoride (PMSF) and 0.035 trypsin inhibitory units/ml aprotinin (pH 7.4) at
4˚C. Resulting homogenates were centrifuged at 15700 g for 40 min at 4˚C to remove insoluble
material. Protein concentration in the supernatant was determined by the BCA assay (BCA
Protein Assay Reagent, Thermo Scientific Pierce). Equal amount of tissue proteins were dena-
tured by boiling 5 min in Laemmli buffer and stored at -20˚C until electrophoresis. HEK293T
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cells were lysed 48 h after transfection at room temperature in Laemmli buffer and sonicated
to shear DNA. Heat treatment of samples was avoided to prevent aggregation of overexpressed
MasR.
Western blotting
The protein extracts were subjected to SDS–PAGE using a Mini Protean apparatus (Bio-Rad
Laboratories, PA, USA) and transferred to polyvinylidenedifluoride (PVDF) membranes. For
heart and kidney tissue, 40 μg of protein homogenates were loaded onto the polyacrylamide
gel whereas for HEK293T cells 25 μg were used.
To reduce non-specific antibody binding, membranes were incubated for 2 h at room tem-
perature in bovine serum albumin (BSA)-based blocking buffer. The membranes were then
exposed to primary antibodies overnight at 4˚C. Only those antibodies recommended for WB
(Fig 1) were tested. Based on the described reactivity we used AAR-013 (1:5000) and sc-
135063 (1:1000), for detection of the MasR present in mouse tissues, while AAR-013, sc-
135063 and sc-54682 1:1000 were used for detection of the human receptor expressed in
HEK293T cells. Anti c-myc tag antibody (Cell Signaling Technology Inc.; cat. #2272) diluted
1:1000 was used to detect the c-myc tagged MasR. Anti-β-tubulin (Abcam Inc.; cat. #Ab6046)
diluted 1:5000 was used as a protein loading control. After incubation for 1 h at room tempera-
ture using a 1:20000 dilution of the appropriate horseradish peroxidase-conjugated secondary
antibody, sc-2004 (anti-rabbit) and sc-2020 (anti-mouse) (Santa Cruz Biotechnology, CA,
USA), reaction products were revealed by enhanced chemiluminescence (ECL Plus, Pierce,
Rockford, IL, USA).
Immunohistochemical staining
Heart and kidneys from MasR-KO and WT mice were prepared by immersion fixation in 10%
buffered formalin, processed for paraffin embedding, and sectioned at a thickness of 4 μm.
Deparaffinized tissue sections were then rehydrated and subjected to antigenic recuperation
with sodium citrate buffer (pH 6.0) at 98˚C for 30 min. Endogenous peroxidase activity was
blocked by incubating slides on PBS containing 3% hydrogen peroxide for 30 min. Non-spe-
cific protein binding was blocked by incubation with PBS containing 1% BSA for 1 h followed
with normal horse serum for 2 h. Heart and kidney sections were incubated with anti-MasR
antibodies recommended for immunohistochemistry [AAR-013 (1:300) and NLS-1531
(1:100)] overnight at 4˚C. Preadsortion control of AAR-013 antibody with the blocking pep-
tide provided by the manufacturers was performed overnight at 4˚C using 10 μg peptide per
1 μg antibody. Negative controls were performed in parallel by replacing the primary antibody
by PBS containing 1% BSA. Subsequently, incubations with biotin-labeled secondary antibod-
ies followed by incubation with streptavidin-horse radish peroxidase complex were each per-
formed for 30 min at room temperature (R.T.U. vectastain kit, Vector Laboratories, CA,
USA). The antigen-antibody binding was visualized with diaminobenzidine (DAB) (Peroxi-
dase substrate kit, DAB sk-4100, Vector Laboratories), and sections were counterstained with
hematoxylin. Immunostained sections were observed under light microscopy using a Leica
DM2000 microscope; representative color photomicrographs were obtained at 40x magnifica-
tion using a Leica DFC400 digital camera and Leica Application Suite software (Leica
Microsystems).
Immunofluorescence
HEK293T cells were washed with PBS 24 h after transfection, fixed in 2% formaldehyde in PBS
for 10 min and permeabilized with 0.2% Triton X-100 in PBS for 15 min. The non-specific
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binding sites were blocked for 30 min with blocking solution (PBS containing 1% BSA, 0.2%
Triton-X-100). Then cells were incubated for 1 h at room temperature with the anti-c-myc
antibody (1:200) or with four different anti-MasR antibodies that were recommended for
immunocytochemistry [NLS-1531, sc-135063 and sc-54682, (diluted 1:200) and AAR-013
(diluted 1:100)]. All dilutions were in the range recommended by the manufacturers. Follow-
ing washing with PBS, cells were incubated with secondary cyanine (Cy3)-conjugated antibody
1:200 for 1 h at room temperature. Donkey Cy3-conjugated IgG (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA) cat # 711-165-152 and # 705-165-003 secondary antibodies
were used to detect rabbit or goat primary antibodies, respectively. After washing with PBS,
the cells were incubated with Hoechst 33258 nucleic acid stain (5 μg/mL) for 10 min. Finally,
the coverslips were washed with PBS and mounted on glass slides with mounting medium.
Images were acquired using a spectral laser scanning confocal Zeiss AxioObserver Z1 LSM710
fluorescent microscope (40X apochromatic, 1.4 NA objective) using dual excitation (543 nm
for Cy3 and 405 nm for Hoechst). Controls prepared by omission of primary antibodies did
not show any Cy3 fluorescence under the above conditions.
RNA isolation and RT-PCR
Total RNA was extracted from heart and kidneys from MasR-KO and WT mice using TRIzol
Reagent (Ambion 1) and then 2 μg of total RNA previously treated with DNase I Amplifica-
tion Grade (InvitrogenTM, CA, USA) were subjected to reverse transcription using iScriptTM
cDNA Synthesis Kit (Bio-Rad Laboratories, Inc.) according to manufacturer´s instructions.
PCR reactions were carried out in a 50 μl reaction volume containing the following reagents:
1 μl of cDNA preparation; 1X Green GoTaq1 Reaction Buffer (Promega); 200 μM of dNTP
Mix (Invitrogen); 1,25 U of GoTaq1 DNA polymerase (Promega), and 0.4 μM of forward and
reverse primers. PCR was performed on a MasterCycler (Eppendorf, Hamburg, Germany),
using the following conditions for denaturation, annealing, and extension (35 cycles): 94˚C for
30 s, 54˚C for 30 s, and 72˚C for 40 s, followed by 72˚C for 5 min. The specific primers
sequences were as follows: for MasR 5´-GGA GAA ATC CCT TCA CGG TC-3´ and 5´-GGA
CAC TAA CAT GAG CGG AG-3´ (Amplicon size: 434 bp); for 18S rRNA 5´-ACGGAC AGG
ATT GAC AGA TT-3´ and 5´-GCC AGA GTC TCG TTC GTT AT-3´ (Amplicon size: 118 bp).
PCR products were separated by electrophoresis on a 2% agarose gel and visualized after stain-
ing with ethidium bromide (0.5 μg/mL).
Results
Detection of MasR mRNA in heart and kidney from wild type and
MasR-KO mice
To verify the absence of MasR in the knockout mice used in these studies, we measured the
amount of MasR mRNA in hearts and kidneys from MasR-KO mice. Reverse transcription
polymerase chain reaction (RT-PCR) analysis showed that MasR mRNA was present in hearts
and kidneys from wild type (WT) mice (Fig 2). In contrast, MasR transcript was undetectable
in either heart (Fig 2A) or kidney (Fig 2B) from MasR-KO mice.
Evaluation of MasR antibodies by Western blotting of heart and kidney
from wild type and MasR-KO mice
We performed a WB analysis using hearts and kidneys protein extracts from WT and MasR-
KO mice. Band patterns produced by two antibodies intended for detection of MasR of mouse
origin in WB studies were compared. As shown in Fig 3, antibody AAR-013 generated three
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bands when exposed to heart homogenates of WT mice. The most prominent one of a MW
ranging from 25 to 37 kDa, another of much lower intensity just above 37 kDa and the third
one between 50 and 75 kDa (Fig 3). When using kidneys homogenates of the same animals,
the AAR-013 yielded three bands of similar intensity, one of a MW ranging from 25 to 37 kDa,
another close to 50 kDa and the third one in the range of 75 kDa (Fig 3). Using the same sam-
ples, antibody sc-135063 generated two bands of high molecular mass, at about 75 kDa (Fig 3).
Thus, it was found that these two antibodies raised against different MasR domains revealed
different patterns of reactivity. Importantly, none of them detected a single band, and only
antibody AAR-013 generated a band of approximately the expected 37 kDa size of the MasR
(Fig 3). Strikingly, in both cases there were no apparent differences in the pattern of reactivity
when hearts and kidneys homogenates from WT and MasR-KO mice were compared (Fig 3).
Evaluation of MasR antibodies by immunohistochemistry of heart and
kidney from wild type and MasR-KO mice
Two antibodies recommended for detection of MasR of mouse origin by IHC were tested. As
shown in Fig 4, tissue sections from hearts and kidneys demonstrated minimal background
Fig 2. Detection of MasR mRNA in heart and kidney from wild type and MasR-KO mice. Representative
agarose gel (n = 3–5) showing reverse transcription polymerase chain reaction (RT-PCR) product obtained
from hearts (A) and kidneys (B) of wild type (WT) and MasR-KO mice. MasR mRNA was undetectable in
heart and kidney of MasR-KO mice. 18S ribosomal RNA (18S rRNA) was used as housekeeping gene.
https://doi.org/10.1371/journal.pone.0183278.g002
Fig 3. Western blot analysis of heart and kidney homogenates from wild type (WT) and MasR-KO
mice. The predicted molecular weight of MasR is about 37 kDa. As observed, the assayed antibodies
generated different immunoreactivity patterns. In both cases there were no differences in the band patterns
obtained with tissues from WT and MAS-KO mice. The membranes are representative of n = 4.
https://doi.org/10.1371/journal.pone.0183278.g003
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staining in the absence of primary antibody, compared with sections incubated with the MasR
antibodies. In heart sections of WT mice (Fig 4A), NLS-1531 antibody stained predominantly
the cytoplasm of cardiomyocytes, attaining similar intensity in WT and MasR-KO hearts (Fig
4A). The AAR-013 antibody generated an intense staining in the nuclei of cardiomyocytes, a
weaker staining was detected in their cytoplasm. Of note, a similar pattern of staining was also
found in heart sections of MasR-KO mice (Fig 4A). In kidney sections of WT mice (Fig 4B),
NLS-1531 antibody staining of WT kidney sections was mostly restricted to cytoplasm of
tubules cells. Strikingly, incubation of NLS-1531 antibody with kidney sections of MasR-KO
mice lead to similar results (Fig 4B). When analyzing the reactivity of the AAR-013 antibody,
we found staining in tubules and glomeruli, with more pronounced nuclear staining and lesser
staining in the cytoplasm (Fig 4B). Although we showed that MasR was absent in MasR-KO, a
similar staining was detected when kidney sections of MasR-KO mice were incubated with
Fig 4. Immunohistochemistry in heart and kidney from wild-type (WT) and MasR-KO mice. Negative
controls performed by omitting the primary antibody demonstrated minimal background immunostaining in
heart (A) and kidney (B) sections. (A) In heart sections, NLS-1531 antibody stained predominantly the
cytoplasm of cardiomyocytes with similar intensity in WT and MasR-KO hearts. The AAR-013 antibody
stained the cardiomyocytes nucleus and weaker staining was observed in their cytoplasm. The same pattern
was found in heart sections of MasR-KO mice. (B) In kidney sections, for NLS-1531 antibody, staining was
mostly restricted to cytoplasm of numerous tubules cells with similar intensity in WT and MasR-KO kidneys.
Antibody AAR-013 stained most intensely tubules cells nucleus and weaker staining was observed in their
cytoplasm. Glomeruli were also stained positively. The same pattern was found in kidney sections of
MasR-KO. Preincubation of the AAR-013 antibody with the blocking peptide provided by the vendors
eliminated the immunohistochemical nuclear staining both in WT and MasR-KO mice kidney sections. Images
are representative of n = 3. Bar, 50 μm.
https://doi.org/10.1371/journal.pone.0183278.g004
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AAR-013 antibody (Fig 4B). Preincubation of the antibody with the blocking peptide provided
by the manufacturers abrogated the nuclear staining in kidney sections from both WT and
MasR-KO mice.
Evaluation of MasR antibodies by immunofluorescence of HEK293T
cells overexpressing MasR
To explore the possibility that the above commented results were a consequence of low sensi-
tivity, we overexpressed the MasR in human embryonic kidney (HEK293T) cells by transfect-
ing them with DNA encoding the human MasR. Total expression and cellular distribution of
MasR protein was evaluated by fluorescence confocal microscopy. We expanded the possibili-
ties of its immunological detection by using a plasmid encoding the MasR fused to the N-ter-
minal c-myc tag. In addition, we used cells transfected with the empty vector as a control. As
shown in Fig 5 an intense c-myc immunostaining was obtained 24 h after transfection, indicat-
ing that the MasR was strongly expressed. A significant amount of the total MasR pool was
present at the plasma membrane. However, a non-plasma membrane-associated MasR pool
was also detectable, especially in cells showing higher levels of receptor expression. Noticeably,
no intranuclear localization of MasR was detected. No c-myc staining was found in cells that
had been transfected with the empty vector.
Next we evaluated the reactivity of four antibodies, suggested for utilization in IF analysis,
towards the human MasR. As shown in Fig 6, antibodies NLS-1531 and sc-54682 generated a
similar staining pattern to that obtained with incubation with the anti c-myc antibody. Both of
them stained predominantly the plasma membrane and also the perinuclear area. No staining
was observed for cells that had been transfected with the empty vector. Antibody sc-135063
also stained the plasma membrane of cells overexpressing MasR. (Fig 6). However, it also gen-
erated widespread signals of lower intensity in overexpressing cells and in cells transfected
Fig 5. Immunofluorescence studies in HEK293T cells overexpressing c-myc tagged MasR using anti
c-myc tag antibody. Images of fluorescence signal corresponding to secondary cyanine (Cy3)-conjugated
antibody (A), nuclear Hoechst 33258 staining (B), merged images (C) and bright field (D) are shown. The
intense immunostaining obtained with the anti c-myc tag antibody indicated strong expression of MasR in
HEK293T cells after transfection with the pcDNA 3.1/c-myc-MasR construct. A significant amount of the total
MasR pool was present at the plasma membrane. No c-myc staining was observed in cells transfected with
the empty vector pcDNA 3.1. Images are representative of 3 independent experiments.
https://doi.org/10.1371/journal.pone.0183278.g005
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with the empty vector. Finally, antibody AAR-013 did not generate any staining associated
with the cell membrane while it revealed intense immunocytochemical staining of identical
distribution and intensity in cells transfected with the empty vector and those transfected with
the pcDNA 3.1/c-myc-MasR construct (Fig 6).
Evaluation of MasR antibodies by Western blotting of HEK293T cells
overexpressing MasR
We also evaluated the ability of the commercial antibodies to detect MasR protein increments
at different levels of overexpression. To that end, HEK293T cells were transfected with increas-
ing amounts of pcDNA 3.1/c-myc-MasR. Cell proteins were solubilized and subjected to WB.
Results are presented in Fig 7. The anti-c-myc antibody revealed a prominent band of a slightly
lower MW than the predicted 37 kDa for the MasR in protein extracts from cells transfected
with 0.2 μg pcDNA 3.1/c-myc-MasR. In protein extracts from cells transfected with 0.5 μg
pcDNA 3.1/c-myc-MasR, a detectable increase in the intensity of this band was observed (Fig
7). In addition, a ladder of higher MW immunoreactive bands was also detected (Fig 7).
Fig 6. Immunofluorescence studies in HEK293T cells overexpressing c-myc tagged MasR using
MasR antibodies. Images of fluorescence signal corresponding to secondary cyanine (Cy3)-conjugated
antibody (A), nuclear Hoechst 33258 staining (B), merged images (C) and bright field (D) are shown. In cells
transfected with the pcDNA 3.1/c-myc-MasR construct, antibodies NLS-1531 and sc-54682 generated a
similar staining pattern to that generated with the anti c-myc antibody. No staining was observed with any of
these antibodies in cells transfected with the empty vector pcDNA 3.1. Antibody sc-135063 was capable of
staining the plasma membrane of cells overexpressing the MasR but also generated widespread signals in
cells transfected with the empty vector. For antibody AAR-013 there was no staining associated with the cell
membrane. Intense immunocytochemical staining of identical distribution and intensity was revealed in cells
transfected with the empty vector and those transfected with the c-myc-MasR construct. Images are
representative of 3 independent experiments.
https://doi.org/10.1371/journal.pone.0183278.g006
Fig 7. Western blotting of HEK293T cells overexpressing c-myc tagged MasR using anti c-myc tag
and three MasR antibodies. Cells were transfected with varying amounts of a plasmid encoding the c-myc-
tagged MasR (0.2 and 0.5 μg of pcDNA 3.1/c-myc-MasR).The anti-c-myc antibody detected a band of 37 kDa
whose intensity increased as higher amount of DNA was transfected (arrow). Additionally, a ladder of higher
molecular weight (MW) immunoreactive bands could be observed (asterisk). sc-54682 antibody reproduced
the band pattern obtained with the c-myc antibody (arrow and asterisk). sc-135063 antibody revealed multiple
bands close to 37 kDa with one of them of increasing intensity as higher amount of DNA was transfected
(arrow) but did not produce a ladder of higher MW immunoreactive bands. High unspecific staining was
attained with sc-135063 antibody. AAR-013 antibody revealed a pattern of immunoreactivity not comparable
to those obtained with the other antibodies. Detection of β-tubulin was used as a protein loading control. The
membranes are representative of 3 independent experiments.
https://doi.org/10.1371/journal.pone.0183278.g007
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Next we evaluated if the band pattern obtained with the anti-c-myc tag antibody could be
reproduced by three commercial antibodies against human MasR suggested for WB. Antibody
AAR-013 revealed a very different pattern of immunoreactivity, a faint band of approximately
37 kDa was detected. Instead, this antibody yielded two prominent bands of both higher (75
kDa) and lower (25 kDa) molecular size (Fig 7). Bands intensity was similar although increas-
ing amounts of pcDNA 3.1/c-myc-MasR were transfected. Antibody sc-135063 revealed multi-
ple bands of MW close to 37 kDa in protein extracts from cells transfected with 0.2 μg pcDNA
3.1/c-myc-MasR. Notably, an increase in the intensity of one of them was observed when cells
were transfected with 0.5 μg pcDNA 3.1/c-myc-MasR (Fig 7). Unlike results obtained with the
anti c-myc tag antibody, sc-135063 antibody did not produce a ladder of immunoreactive
bands of higher MW. Instead, it generated bands of higher MW (50 and 75 kDa respectively)
that had similar intensity regardless of the amount of pcDNA 3.1/c-myc-MasR plasmid used
for transfection (Fig 7). Finally, sc-54682 antibody generated a similar band pattern to that
obtained with the anti-c-myc antibody. As shown in Fig 7, sc-54682 antibody revealed a band
of around 37 kDa in protein extracts from cells transfected with 0.2 μg pcDNA 3.1/c-myc-
MasR. The intensity of this band increased when cells were transfected with 0.5 μg pcDNA
3.1/c-myc-MasR (Fig 7). Similarly to the pattern obtained with the anti c-myc antibody, sc-
54682 generated a ladder of immunoreactive bands of higher MW. We observed an additional
band above 50 kDa, whose intensity remained unaltered despite transfecting increasing
amounts of pcDNA 3.1/c-myc-MasR.
Discussion
During the last two decades, antibodies towards MasR have been widely used in scientific
reports aimed to understand its molecular regulation in a variety of physiological and patho-
physiological conditions. At the same time, uncertainties about the usefulness of several
GCPRs antibodies, such as those against AT1 and AT2 receptors have been raised [25–36]. As
an adequate validation analysis was lacking, we carried on an evaluation of four commercial
MasR polyclonal antibodies following previously established criteria. During the last phase of
this study, Santa Cruz Biotechnology discontinued a large number of its polyclonal products
including two of the four assayed antibodies. However, these Santa Cruz polyclonal antibodies
may still be available in several research laboratories. More importantly, a validation analysis is
crucial to interpret previously published work using them.
A major criterion in locating a valid antibody is that the precise antigen sequence against
which the antibody was raised should be provided. Full information for each antibody should
be known and included into the methods section of scientific publication to assure that the
experiments are repeatable [39–42]. Two of the MasR antibodies studied, AAR-013 and sc-
135063, raised against different domains of the receptor, met this criterion (Fig 1). The other
two antibodies (sc-54682 and NLS-1531), were provided without the exact sequence of the
immunizing peptide but with a statement that they were raised against part of the N- terminal
and C-terminal domain, respectively.
Immunoblotting provides a sensitive and discriminating method for antibody validation
because it clearly distinguishes crossreacting proteins of different molecular sizes. In tissues
expressing the MasR, antibodies should detect a single band at the predicted MW (*37 kDa).
For our study we used two rodent tissues (heart and kidney) which are known to express the
MasR. None of the two antibodies intended for detection of MasR of mouse origin in WB
studies, sc-135063 and AAR-013 antibodies, detected a single band, and only AAR-013 gener-
ated a band of approximately the expected 37 kDa size of the receptor. The detection of multi-
ple bands or bands of a MW different from the predicted, could be indicative of recognition of
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MasR in different states of posttranslational modifications, in oligomeric forms or breakdown
products. In any case, the use of such an antibody requires verification with antibodies against
a different part of the molecule to demonstrate that the staining is genuine [39]. In each tissue,
the two mentioned antibodies raised against different MasR domains revealed different pat-
terns of reactivity. The high variability on the ability of the different antibodies to recognize
these bands raised the concern that each antibody binds to distinct unknown proteins of
diverse molecular sizes other than the MasR.
The reactivity of a given antibody with its target protein depends, among other factors, on
the abundance of that protein in the preparation [42]. Accordingly, we performed the most
stringent control for antibody specificity that requires comparison of antibody reactivity in
WT tissues with low physiological receptor expression densities to reactivity in KO animals in
which endogenous MasR protein expression has been genetically deleted. We verified by
RT-PCR analysis that the MasR-KO mice used in the current study were truly deficient in this
receptor, as MAS transcripts were undetectable in both the heart and the kidney of this animal
model. Strikingly, the two analyzed antibodies showed the same pattern of bands when hearts
and kidneys homogenates from WT and MasR-KO mice were compared. These results indi-
cate that the immunoreactivity observed is not related to the presence or absence of the MasR
and that each of these antibodies react with multiple off-targets proteins. In MasR-KO mice,
the MAS gene was disrupted by insertion of a neomycin resistance cassette resulting in dele-
tion of the region coding for the amino-terminal 253 amino acids of the receptor including six
transmembrane domains [10]. Therefore, it is possible that some antibodies may interact with
non-functional fragments of the protein potentially expressed in MasR-KO mice. However, we
believe this would not be the case, considering that AAR-013 and sc-135063 antibodies were
raised against amino acids 212–224 and 1–117, respectively. These sequences correspond to
domains of the MasR that were untranslated in the MasR-KO mice used. The identity of the
proteins recognized by these antibodies remains unknown. Our study design does not allow us
to rule out that the bands yielded by the antibodies correspond to related proteins, structurally
homologous to MasR that could potentially be upregulated in MasR-KO mice. In summary,
results obtained from these experiments suggested that the analyzed MasR antibodies were
unable to detect the endogenous MasR in heart and kidney from mice using conditions tradi-
tionally employed for conventional WB analysis. This conclusion is directly applicable only for
the mentioned mice tissues. Staining in tissues from other species may still represent other
antigens (not present in mice) and hence require additional controls.
While this type of antibody validation was a useful first step, it only provided data for WB
studies. There is no absolute correlation between the specificity of the labeling in WB and
IHC, so it was necessary to demonstrate the usefulness of MasR antibodies for this latter appli-
cation. Accordingly, we performed IHC studies using antibodies AAR-013 and NLS-1531 that
were recommended by the vendors for this application. In heart and kidney from WT mice,
each antibody provided different tissue and cell localization staining. Strikingly, in all cases the
staining patterns obtained for each tissue were identical for both WT and MasR-KO mice. The
labeling pattern obtained after an immunohistochemical reaction depends not only on the pri-
mary antibody, but on the whole experimental procedure, that can affect final outcome includ-
ing methods used for tissue fixation and antigen retrieval [41,43]. It is important to note that
in the current study, experiments were performed following NLS-1531 antibody manufacturer
´s instructions as AAR-013 antibody manufacturer did not provide any recommendation. In
this context, the fact that the labeling pattern was identical in tissues from both WT and
MasR-KO suggests that under our experimental conditions the labeling obtained with both
antibodies is not specific. Still, we do not exclude the possibility that one of the antibodies used
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here and resulting in false-positive labelling may prove to be useful under conditions that have
not been evaluated yet.
A criterion used to validate antibody specificity applied very often is the disappearance of
staining in the presence of a blocking peptide, i.e the peptide against which the antibody was
obtained. This control is also typically cited in antibody specification data sheets by commer-
cial suppliers. However, current data raises questions about the validity of this test. Indeed,
when AAR-013 antibody was preadsorbed with the available target peptide, the immunoreac-
tivity of WT kidney sections was abolished. This result contrasts with the lack of specificity
demonstrated in tissues from MasR-KO mice, the most stringent test of validity employed.
Thus, the disappearance of staining only assures that AAR-013 antibody recognizes the peptide
against which it was raised. In keeping with these results, blocking peptides had been used
with several GPCR antibodies which were found not to be selective upon more stringent vali-
dation [25,27,28,30,33,34,42]. Furthermore, antigen preadsorption of AAR-013 antibody also
blocked labeling of MasR-KO kidneys sections. This implies that not only on-target but also
off-target binding activity of the antibody was inhibited by preadsorption with the blocking
peptide. Our findings are in agreement with current reports that consider that this test is not
sufficient evidence to claim specificity because it does not tell if the observed labeling repre-
sents a specific visualization of the antigen under study or it is the consequence of cross-reac-
tion with other molecules.
To assess the possibility that obtained results were attributable to low sensitivity of the anti-
bodies, we used HEK293T cells overexpressing c-myc-tagged human MasR. Confocal fluores-
cence images obtained after incubation with an anti c-myc antibody showed that a significant
amount of the total MasR pool localized to the plasma membrane. The detectable non-plasma
membrane-associated MasR pool probably represents newly synthesized molecules passing
through the secretory pathway. Noticeable, intranuclear localization of the receptor was not
observed. This cellular pattern of distribution of the MasR was similar to the findings previ-
ously reported when using MasR-GFP [44] and c-myc-MasR [20] constructs. Accordingly, we
tested four MasR antibodies, all of them recommended for detection of the human receptor by
IF. Noteworthy, sc-54682, sc-135063 and NLS-1531 antibodies generated a similar staining
pattern to the c-myc antibody. These results indicated that these antibodies, raised against N-
terminal or C-terminal domains of the MasR, were able to detect this protein at high levels in
the transfected cell line. At the same time, they allowed us to verify appropriate full-length
MasR protein expression in HEK 293T cells. However, sc-135063 antibody also generated wide-
spread signals of lower intensity in cells overexpressing MasR and cells transfected with the
empty vector. Thus, although the relative abundance of the target was increased by overexpres-
sing the MasR, this antibody yielded a lower signal-to-noise ratio. Finally, AAR-013 antibody
was unable to detect the specific immunoreactive MasR protein because immunofluorescence
staining showed identical distribution and intensity in cells transfected with the human MasR
cDNA or with the empty expression vector. We also evaluated the ability of commercial anti-
bodies to detect MasR protein increments at different levels of overexpression by WB. The anti
c-myc antibody detected a 37 kDa band, consistent with the expected size of the monomer form
of the MasR. The intensity of this band increased as higher amount of DNA was transfected,
providing stronger evidence that it accounts for distinct amounts of myc-tagged MasR. Addi-
tionally, a ladder of higher MW immunoreactive bands was obtained that could represent the
receptor in different states of posttranslational modification (e.g. glycosylation, ubiquitination),
in oligomeric forms or in aggregates formed during the denaturation step inherent to this kind
of approach. A similar band pattern has been previously reported for dopamine receptors [45].
When we tested the MasR antibodies, we found that sc-54682 reproduced the band pattern
obtained with the c-myc antibody. On the other hand, sc-135063 antibody revealed multiple
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bands close to 37 kDa with one of them of increasing intensity as higher amount of DNA was
transfected but did not produce a ladder of higher MW immunoreactive bands. Besides, high
unspecific staining was attained with sc-135063 antibody. Finally, AAR-013 antibody revealed a
very different pattern of immunoreactivity. These results obtained by WB were in agreement
with IF assays.
It is expected for MasR antibodies to detect their target over a wide range of receptor densi-
ties. We conclude that sc-54682 and sc-135063 antibodies were able to detect MasR protein of
human origin when tested on a cell line with marked overexpression either by IF or by WB.
However, for sc-135063 antibody, high unspecific staining was observed when tested by both
techniques. NLS-1531 antibody (recommended for IF) was also able to detect human MasR by
this technique. Because only sc-135063 and NLS-1531 antibodies were reported to detect
MasR of mouse origin, they could be tested in mice tissues by WB and IHC, respectively. In
this condition, when much lower physiological expression densities were assessed, these two
antibodies were unable to detect their target. These results suggest poor sensitivity of sc-
135063 and NLS-1531 antibodies for MasR. One antibody (sc-54682) could be tested only
upon overexpression because of its unique reported reactivity towards human MasR. The fail-
ure of AAR-013 antibody to detect MasR either at the low expression levels occurring physio-
logically or at the higher expression levels observed in transfected cells does not appear to be
an issue of insufficient sensitivity. As a consequence, validated antibodies able to detect endog-
enous MasR are still lacking.
In summary, this is the first study focused in the characterization of MasR antibodies for
utilization in Western Blotting, immunofluorescence and immunohistochemistry studies.
Continuous efforts are needed to develop sensitive and specific antibodies to MasR and it is
recommended that the newly developed antibodies to MasR be validated before their
application.
Conclusions
We demonstrated that three commercial antibodies that were able to detect MasR protein at
the high expression levels observed in a transfected cell line failed to detect this receptor in
rodent tissues at physiological abundance. This finding supports the idea that specificity of an
antibody cannot be generally claimed from a model system and should be evaluated not only
for each application and experimental condition but also upon different expression levels of
the target. Knowledge of MasR tissue distribution and abundance is a critical issue in the pro-
cess of understanding its function. Our current study questions the validity of using any of
these antibodies for detection of the endogenous MasR. Interpretations of previously pub-
lished work based on qualitative and/or quantitative estimations of the MasR protein using
these antibodies should be re-evaluated and considered with rigorous caution. Without a reli-
able antibody, alternative methods, such as quantitative real-time–polymerase chain reaction,
Northern blot or in situ hybridization should be used. While specific labelled ligands have
been extremely useful for studies of many endogenous GPCRs [33], binding experiments spec-
ificity using labeled Ang-(1–7) is currently under discussion [9, 18, 23, 46, 47]. Thus, antibod-
ies are one of the best tools to study MasR localization and protein abundance. In many cases
researchers must use an antibody with no reliable information regarding its usefulness for
their application. It is important that the companies inform in detail the conditions in which
antibodies should be used according to their application to avoid erroneous data like those
exposed in these series of mentioned articles. Successful strategies to generate highly specific
and broadly applicable antibodies against the MasR appear to be a high priority task to con-
tinue research on this field.
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Supporting information
S1 Fig. Original uncropped and unadjusted agarose gels corresponding to Fig 2 from the
main text. Ladders and their base pair lengths are shown.
(TIF)
S2 Fig. Original uncropped and unadjusted blots corresponding to Fig 3 from the main
text. Molecular size markers are shown. Red boxes indicate the areas included in Fig 3. WT:
wild type, MasR-KO: Mas receptor knockout, X: any sample.
(TIF)
S3 Fig. Original uncropped and unadjusted blots corresponding to Fig 7 from the main
text. Molecular size markers are shown. Red boxes indicate the areas included in Fig 7. WT:
wild type, MasR-KO: Mas receptor knockout, X: any sample.
(TIF)
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